Argenx Se (ARGX) Prepaid Assets (2015 - 2026)
Argenx Se (ARGX) posted quarterly Prepaid Assets of $572.0 million for Q2 2026, down 99.84% year-on-year from $362.7 billion in Q2 2025, and up 74.39% on a QoQ basis from $328.0 million in Q4 2025.
Argenx Se (ARGX) Prepaid Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Prepaid Assets for 12 consecutive years, with $572.0 million the latest figure, recorded in Q2 2026.
- Quarterly Prepaid Assets fell 99.84% year-over-year to $572.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $572.0 million (down 99.84% YoY) and the FY2025 annual result came in at $328.0 million, up 74.52% from the prior year.
- Prepaid Assets climbed to $572.0 million in Q2 2026 per ARGX's latest filing, from $328.0 million in the prior quarter.
- Over the last five years, Prepaid Assets for ARGX reached as high as $362.7 billion in Q2 2025 and fell as low as $76.0 million in Q4 2022.
- A 5-year average of $40.5 billion and a median of $179.4 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2025 — Prepaid Assets jumped 202059.74% — and 2026, when it slumped 99.84%.
- Year by year, Prepaid Assets stood at $76.0 million in 2022, then jumped by 76.36% to $134.1 million in 2023, then jumped by 40.18% to $187.9 million in 2024, then jumped by 74.52% to $328.0 million in 2025, then soared by 74.39% to $572.0 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $572.0 million, $328.0 million, and $362.7 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 572.00 Mn |
| Dec 31, 2025 | 328.00 Mn |
| Jun 30, 2025 | 362.72 Bn |
| Dec 31, 2024 | 187.95 Mn |
| Jun 30, 2024 | 179.42 Mn |
| Dec 31, 2023 | 134.07 Mn |
| Jun 30, 2023 | 138.83 Mn |
| Dec 31, 2022 | 76.02 Mn |
| Jun 30, 2022 | 82.31 Mn |
| Dec 31, 2021 | 58.95 Mn |
| Jun 30, 2021 | 62.40 Mn |
| Dec 31, 2020 | 25.89 Mn |
| Jun 30, 2020 | 12.36 Mn |
| Dec 31, 2019 | 10.27 Mn |
| Jun 30, 2019 | 9.47 Mn |
| Dec 31, 2018 | 3.41 Mn |
| Jun 30, 2018 | 6.81 Mn |
| Dec 31, 2017 | 3.37 Mn |
| Jun 30, 2017 | 3.41 Mn |
| Dec 31, 2016 | 3.10 Mn |